Page last updated: 2024-08-18

allylamine and Dyslipidemia

allylamine has been researched along with Dyslipidemia in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (60.00)	29.6817
2010's	2 (40.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bangit, JR; Batsell, RR; Miraskar, RA; Reddy, KJ; Singh, M; Zaheer, MS	1
Levy, P	1
Insull, W	1
Armani, A; Toth, PP	1
Davidson, MH	1

Reviews

4 review(s) available for allylamine and Dyslipidemia

Article	Year
Review of studies on the effect of bile acid sequestrants in patients with type 2 diabetes mellitus. Metabolic syndrome and related disorders, 2010, Volume: 8 Suppl 1 Topics: Adult; Allylamine; Anticholesteremic Agents; Bile Acids and Salts; Cholesterol, LDL; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dyslipidemias; Humans	2010
Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. Southern medical journal, 2006, Volume: 99, Issue:3 Topics: Allylamine; Bile Acids and Salts; Cholesterol; Colesevelam Hydrochloride; Colestipol; Dyslipidemias; Humans; Hypolipidemic Agents; Lipids; Treatment Outcome	2006
Colesevelam hydrochloride in the management of dyslipidemia. Expert review of cardiovascular therapy, 2006, Volume: 4, Issue:3 Topics: Allylamine; Anion Exchange Resins; Anticholesteremic Agents; Azetidines; Colesevelam Hydrochloride; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Patient Compliance	2006
The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:15 Topics: Allylamine; Animals; Anticholesteremic Agents; Cholesterol, LDL; Colesevelam Hydrochloride; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors	2007

Other Studies

1 other study(ies) available for allylamine and Dyslipidemia

Article	Year
Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy. Preventive cardiology, 2010,Summer, Volume: 13, Issue:3 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Allylamine; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol, LDL; Colesevelam Hydrochloride; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fatty Acids, Omega-3; Female; Humans; Inflammation; Life Style; Male; Middle Aged; Niacin; Regression Analysis; Retrospective Studies; Risk Factors; Simvastatin; Statistics as Topic; Vitamin B Complex	2010

Article

Year

Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy.

Preventive cardiology, 2010,Summer, Volume: 13, Issue:3

Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Allylamine; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol, LDL; Colesevelam Hydrochloride; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fatty Acids, Omega-3; Female; Humans; Inflammation; Life Style; Male; Middle Aged; Niacin; Regression Analysis; Retrospective Studies; Risk Factors; Simvastatin; Statistics as Topic; Vitamin B Complex

2010